Compare ResMed Inc. (RMD) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tesla, Inc. — how do they compare? ResMed Inc. trades at $225.22 (market cap $32.61B), while Tesla, Inc. trades at $327 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 40.2× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| RMD | TSLA | |
|---|---|---|
Market Cap | $32.61B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $293.73 | $489.88 |
52-Week Low | $182.82 | $298.16 |
Enterprise Value | $31.97B | $1.29T |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Tesla (TSLA) trades at $326.58, down 1.3% over the past 24 hours, with a bearish technical signal driven by moving averages. The stock shows elevated valuation ratios, including a P/E of 308.16 and P/S of 11.36, while recent earnings performance was mixed with a Q2 2026 miss. Cash flow trends indicate heavy capital expenditure, and revenue growth has slowed, with net income margin at 3.67% for 2025. Recent news highlights regulatory approval for driver-assistance software in Europe and discussions on Tesla's strategic pivot toward AI and robotics.
Tesla faces near-term headwinds from valuation concerns and competitive pressures, but long-term growth potential hinges on autonomous driving technology and energy segment expansion. Key risks include execution challenges in new business lines and macroeconomic sensitivity. Analyst consensus is mixed with a $393.87 price target, suggesting cautious optimism amid high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
